Sugi Predict

Sugi Predict / Compounds / SCHEMBL4337983

SCHEMBL4337983

SCHEMBL4337983

[c]1nc2cccc(-c3ccccc3)c2s1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIMK1 P53667 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ BCL2L1 Q07817 1/20 0.34
▸ CYP2A6 P11509 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ METAP2 P50579 1/20 0.33
▸ TNF P01375 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ CSF1R P07333 1/20 0.33
▸ FGFR1 P11362 1/20 0.33
▸ PDGFRA P16234 1/20 0.33
▸ LTK P29376 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ MAPK8 P45983 1/20 0.33
▸ CSNK1A1 P48729 1/20 0.33
▸ CDK5 Q00535 1/20 0.33
▸ ACVR1 Q04771 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544603 0.82 ACACA (0.44) ALDH1A1HPGDL3MBTL1AURKBCLK4
SCHEMBL5547672 0.80 MAPT (0.45) ALDH1A1HSD17B10HPGDCYP2A6MAPK1
SCHEMBL1894942 0.72 CYP1A2 (0.32) ALDH1A1CYP2A6CYP1A2
SCHEMBL1359392 0.72 BACE1 (0.37) BACE1
SCHEMBL1359399 0.72 PSMB8 (0.41) CYP2A6CYP1A2
SCHEMBL11516596 0.69 ALDH1A1 (0.45) LIMK1ALDH1A1HSD17B10HPGDBCL2L1
SCHEMBL4337978 0.69 LIMK1 (0.39) LIMK1ALDH1A1HSD17B10HPGDBCL2L1
SCHEMBL7149380 0.69 BACE1 (0.41) LIMK1ALDH1A1HSD17B10HPGDBCL2L1
SCHEMBL3383561 0.68 NQO2 (0.46) ALDH1A1HPGDFGFR1MEN1RAB9A
SCHEMBL14860945 0.67 ASH1L (0.62) LIMK1ALDH1A1HSD17B10L3MBTL1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US claimed
US-20200317691-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2020-10-08 — — US claimed
EP-3414239-A2 INHIBITORS OF RECEPTOR-INTERACTING PROTEIN KINASE 1 Denali Therapeutics Inc. (US) 2018-12-19 — — EP claimed
US-10131676-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2018-11-20 — — US claimed
US-20180099981-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-04-12 — — US claimed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US claimed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO claimed
US-20240150376-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2024-05-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
CN-114437105-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-05-06 — — CN disclosed
CN-109071504-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-03-08 — — CN disclosed
US-20200317691-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2020-10-08 — — US disclosed
US-10604535-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2020-03-31 — — US disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 — — EP disclosed
EP-2032543-A1 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES Boehringer Ingelheim International GmbH (DE) 2009-03-11 — — EP disclosed
WO-2007146977-A1 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-12-21 — — WO disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LIMK1 3800/4885ALDH1A1 355/4885HSD17B10 467/4885
US-20180099981-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB LIMK1 554/4885ALDH1A1 4405/4885HSD17B10 2725/4885
US-20200317691-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB LIMK1 554/4885ALDH1A1 4405/4885HSD17B10 2725/4885
US-20240150376-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB LIMK1 554/4885ALDH1A1 4405/4885HSD17B10 2725/4885
US-10131676-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB LIMK1 554/4885ALDH1A1 4405/4885HSD17B10 2725/4885
US-20230043400-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB LIMK1 554/4885ALDH1A1 4405/4885HSD17B10 2725/4885
US-10604535-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB LIMK1 554/4885ALDH1A1 4405/4885HSD17B10 2725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.